DK3209295T4 - Fremgangsmåder til behandling af øjenlidelser - Google Patents

Fremgangsmåder til behandling af øjenlidelser Download PDF

Info

Publication number
DK3209295T4
DK3209295T4 DK15852340.7T DK15852340T DK3209295T4 DK 3209295 T4 DK3209295 T4 DK 3209295T4 DK 15852340 T DK15852340 T DK 15852340T DK 3209295 T4 DK3209295 T4 DK 3209295T4
Authority
DK
Denmark
Prior art keywords
treatment
methods
eye disorders
disorders
eye
Prior art date
Application number
DK15852340.7T
Other languages
Danish (da)
English (en)
Other versions
DK3209295T3 (da
Inventor
Douglas Michael Ackermann Jr
James Loudin
Kenneth J Mandell
Original Assignee
Oyster Point Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55748136&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3209295(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oyster Point Pharma Inc filed Critical Oyster Point Pharma Inc
Application granted granted Critical
Publication of DK3209295T3 publication Critical patent/DK3209295T3/da
Publication of DK3209295T4 publication Critical patent/DK3209295T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Emergency Medicine (AREA)
DK15852340.7T 2014-10-20 2015-10-19 Fremgangsmåder til behandling af øjenlidelser DK3209295T4 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462066280P 2014-10-20 2014-10-20
US201562100844P 2015-01-07 2015-01-07
PCT/US2015/056273 WO2016064759A1 (en) 2014-10-20 2015-10-19 Methods of treating ocular conditions

Publications (2)

Publication Number Publication Date
DK3209295T3 DK3209295T3 (da) 2021-03-01
DK3209295T4 true DK3209295T4 (da) 2024-02-26

Family

ID=55748136

Family Applications (2)

Application Number Title Priority Date Filing Date
DK15852340.7T DK3209295T4 (da) 2014-10-20 2015-10-19 Fremgangsmåder til behandling af øjenlidelser
DK20212556.3T DK3848028T5 (da) 2014-10-20 2015-10-19 Fremgangsmåder til behandling af øjenlidelser

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK20212556.3T DK3848028T5 (da) 2014-10-20 2015-10-19 Fremgangsmåder til behandling af øjenlidelser

Country Status (21)

Country Link
US (14) US9504644B2 (enExample)
EP (3) EP3848028B9 (enExample)
JP (3) JP6873906B2 (enExample)
KR (2) KR102601505B1 (enExample)
CN (3) CN107106542B (enExample)
AU (2) AU2015336216B2 (enExample)
BR (2) BR112017008097B1 (enExample)
CA (1) CA2965129C (enExample)
DK (2) DK3209295T4 (enExample)
EA (1) EA035335B1 (enExample)
ES (2) ES2848977T5 (enExample)
FI (1) FI3848028T3 (enExample)
IL (3) IL293188B2 (enExample)
MX (2) MX392383B (enExample)
MY (1) MY186870A (enExample)
PH (1) PH12017500602A1 (enExample)
PL (1) PL3848028T3 (enExample)
PT (2) PT3848028T (enExample)
SG (2) SG10202011669PA (enExample)
WO (1) WO2016064759A1 (enExample)
ZA (1) ZA201703467B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3848028T (pt) 2014-10-20 2024-09-20 Oyster Point Pharma Inc Métodos de tratamento de estados oculares
DK3439661T3 (da) * 2016-04-07 2021-10-18 Oyster Point Pharma Inc Fremgangsmåder til behandling af øjenlidelser
EP3820443A1 (en) 2018-07-10 2021-05-19 Oyster Point Pharma, Inc. Combinations of positive allosteric modulators and nicotinic acetylcholine receptor agonists for treating ocular conditions
WO2020014217A1 (en) * 2018-07-10 2020-01-16 Oyster Point Pharma, Inc. Methods of treating ocular conditions
ES3039903T3 (en) 2020-04-28 2025-10-27 Oyster Point Pharma Inc Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections
WO2025037323A1 (en) * 2023-08-12 2025-02-20 Pavan Kumar Kothapuvari Pharmaceutical compositions for treatment of dry eye disease and associated disorders
DE102023208057A1 (de) * 2023-08-23 2025-02-27 Ursapharm Arzneimittel Gmbh Ophthalmologische zusammensetzung enthaltend mindestens einen nikotinischen acetylcholinrezeptor-agonist zur topischen applikation am auge bei der prävention oder behandlung von entzündungen am auge

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277855B1 (en) 2000-04-21 2001-08-21 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
US20030008892A1 (en) 2001-07-09 2003-01-09 Pfizer Inc. Pharmaceutical composition and method of modulating cholinergic function in a mammal
KR20040066140A (ko) 2001-11-29 2004-07-23 화이자 프로덕츠 인크. 5,8,14-트리아자테트라시클로[10.3.1.0(2,11).0(4,9)]헥사데카-2(11),3,5,7,9-펜타엔의 숙신산염 및 그의 제약 조성물
WO2004039366A1 (en) 2002-11-01 2004-05-13 Pharmacia & Upjohn Company Llc Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
US20060270592A1 (en) * 2004-03-19 2006-11-30 Ophthalmic Research Associates, Inc. Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
CA2583101A1 (en) 2004-10-15 2006-04-20 Pfizer Products Inc. Compositions and methods for intranasal, buccal, sublingual and pulmonary delivery of varenicline
EP1827373B1 (en) * 2004-11-09 2008-12-03 Novagali Pharma SA Ophthalmic emulsions containing prostaglandins
WO2006100075A2 (en) * 2005-03-22 2006-09-28 Niconovum Ab Use of an artificial sweetener to enhance absorption of nicotine
US20110086086A1 (en) 2005-07-26 2011-04-14 Pfizer Inc Transdermal system for varenicline
EP1928484B1 (en) 2005-08-26 2010-02-24 The Board Of Trustees Of The Leland Stanford Junior University Methods for treatment of headaches by administration of oxytocin
CA2623940C (en) 2005-09-27 2017-01-10 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and methods of use
TWI454262B (zh) 2006-11-02 2014-10-01 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
US20080132475A1 (en) * 2006-12-05 2008-06-05 Charles Gerald Connor Treatment for dry eye
CA2676670C (en) * 2007-02-02 2012-03-13 Pfizer Products Inc. Tricyclic compounds, compositions, and methods
EP1977746B8 (en) * 2007-04-02 2014-09-24 Parkinson's Institute Methods and compositions for reduction of side effects of therapeutic treatments
US20090093446A1 (en) 2007-10-05 2009-04-09 Winston Laboratories, Inc. Method for alleviating keratoconjunctivitis sicca
CL2008003507A1 (es) * 2007-11-26 2009-11-27 Neuroderm Ltd Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico.
US20090215787A1 (en) 2008-02-22 2009-08-27 Mai De Ltd. Preparations of new polymorphic forms of varenicline tartrate
CA2716863A1 (en) 2008-03-05 2009-09-11 Targacept, Inc. Sub-type selective amides of diazabicycloalkanes
EP2344496A1 (en) * 2008-09-05 2011-07-20 Targacept Inc. Amides of diazabicyclooctanes and uses thereof
WO2010028011A1 (en) 2008-09-05 2010-03-11 Targacept, Inc. Amides of diazabicyclononanes and uses thereof
ES2820857T3 (es) 2008-12-01 2021-04-22 Oyster Point Pharma Inc Síntesis y formas de sal novedosas de (R)-5-((E)-2-pirrolidin-3-ilvinil)pirimidina
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
US20110274628A1 (en) 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
US8821457B2 (en) * 2010-09-08 2014-09-02 Johnson & Johnson Vision Care, Inc. Punctal plug containing drug formulation
US20140170157A1 (en) * 2011-06-15 2014-06-19 Glaxosmithkline Intellectual Property (No.2) Limited Method of selecting therapeutic indications
EP2727604A4 (en) * 2011-06-30 2015-03-18 Toray Industries ANTIPRURIGINOUS AGENT
CA3083244C (en) * 2011-10-20 2023-01-03 Novartis Ag Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment
WO2013080196A1 (en) * 2011-11-30 2013-06-06 D.E.S. Diagnostics Ltd. Dry eye diagnostic
ES2426517B1 (es) * 2012-04-20 2014-05-14 Genetracer Biotech S.L Método para predecir la seguridad de un tratamiento farmacológico
HUE034886T2 (hu) 2013-03-15 2018-03-28 Glia Llc Gyógyszerek cranialis adagolása
AU2014253754C1 (en) 2013-04-19 2015-07-30 Oculeve, Inc. Nasal stimulation devices and methods
PT3848028T (pt) 2014-10-20 2024-09-20 Oyster Point Pharma Inc Métodos de tratamento de estados oculares
DK3439661T3 (da) 2016-04-07 2021-10-18 Oyster Point Pharma Inc Fremgangsmåder til behandling af øjenlidelser
WO2020014217A1 (en) 2018-07-10 2020-01-16 Oyster Point Pharma, Inc. Methods of treating ocular conditions
EP3820443A1 (en) 2018-07-10 2021-05-19 Oyster Point Pharma, Inc. Combinations of positive allosteric modulators and nicotinic acetylcholine receptor agonists for treating ocular conditions

Also Published As

Publication number Publication date
WO2016064759A1 (en) 2016-04-28
IL251769A0 (en) 2017-06-29
PT3209295T (pt) 2021-02-05
CN111956803A (zh) 2020-11-20
MX2017005064A (es) 2018-02-23
EP3209295B1 (en) 2020-12-09
US20160106746A1 (en) 2016-04-21
US20220233528A1 (en) 2022-07-28
IL251769B (en) 2022-06-01
US20250255865A1 (en) 2025-08-14
SG10202011669PA (en) 2020-12-30
US11903941B2 (en) 2024-02-20
CA2965129C (en) 2024-03-12
US9532944B2 (en) 2017-01-03
US20250235449A1 (en) 2025-07-24
CN107106542B (zh) 2020-05-08
US20170239244A1 (en) 2017-08-24
IL318427A (en) 2025-03-01
PH12017500602A1 (en) 2017-09-04
IL293188A (en) 2022-07-01
ES2848977T5 (es) 2024-06-06
AU2015336216A1 (en) 2017-06-08
US20160106744A1 (en) 2016-04-21
CN111956650B (zh) 2024-06-04
BR112017008097B1 (pt) 2023-03-28
BR112017008097A2 (pt) 2018-02-20
EA035335B1 (ru) 2020-05-28
US20250275963A1 (en) 2025-09-04
DK3209295T3 (da) 2021-03-01
US10456396B2 (en) 2019-10-29
JP2023024574A (ja) 2023-02-16
KR20230042144A (ko) 2023-03-27
JP2017531044A (ja) 2017-10-19
EP3209295B2 (en) 2023-12-06
EP3848028B9 (en) 2024-10-16
US20200246336A1 (en) 2020-08-06
IL293188B1 (en) 2025-02-01
ES2848977T3 (es) 2021-08-13
US9597284B2 (en) 2017-03-21
US9504644B2 (en) 2016-11-29
US11903943B2 (en) 2024-02-20
FI3848028T3 (fi) 2024-08-21
US11224598B2 (en) 2022-01-18
EP3848028B1 (en) 2024-05-29
PT3848028T (pt) 2024-09-20
ZA201703467B (en) 2023-12-20
AU2020213351A1 (en) 2020-08-27
US9504645B2 (en) 2016-11-29
MX392383B (es) 2025-03-24
EP4413974A3 (en) 2024-10-09
CN111956650A (zh) 2020-11-20
JP6873906B2 (ja) 2021-05-19
CN111956803B (zh) 2025-10-31
KR102601505B1 (ko) 2023-11-14
DK3848028T3 (da) 2024-08-26
DK3848028T5 (da) 2025-01-20
EP3209295A4 (en) 2018-05-23
JP7502404B2 (ja) 2024-06-18
US20160106745A1 (en) 2016-04-21
EP3848028A1 (en) 2021-07-14
US20230226054A1 (en) 2023-07-20
IL293188B2 (en) 2025-06-01
US20230226052A1 (en) 2023-07-20
MY186870A (en) 2021-08-26
EP4413974A2 (en) 2024-08-14
AU2020213351B2 (en) 2023-04-06
CN107106542A (zh) 2017-08-29
CA2965129A1 (en) 2016-04-28
EA201790893A1 (ru) 2018-01-31
US11903942B2 (en) 2024-02-20
JP7257371B2 (ja) 2023-04-13
SG11201703135XA (en) 2017-05-30
ES2986830T3 (es) 2024-11-12
AU2015336216B2 (en) 2020-05-21
KR102511955B1 (ko) 2023-03-22
US20230226053A1 (en) 2023-07-20
US11911380B2 (en) 2024-02-27
BR122022025737B1 (pt) 2023-12-26
MX2022005888A (es) 2022-06-14
PL3848028T3 (pl) 2024-11-18
KR20170086040A (ko) 2017-07-25
US20160106665A1 (en) 2016-04-21
EP3209295A1 (en) 2017-08-30
JP2021038250A (ja) 2021-03-11
US20240173318A1 (en) 2024-05-30

Similar Documents

Publication Publication Date Title
DK3851537T3 (da) Behandling af hyperbilirubinæmi
DK3450553T3 (da) Mrna-terapi til behandling af øjensygdomme
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
DK3718507T3 (da) Anordninger til behandling af nedre ekstremitetsvaskulatur
DK3171928T3 (da) Stimulationsmønstre til behandling af tørt øje
DK3185876T3 (da) Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3137169T3 (da) Hæmmere af lysin-specifik demethylase-1
DK3125875T3 (da) Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande
DK3265085T3 (da) Fremgangsmåder til behandling af forstyrrelser med abnorme ufrivillige bevægelser
DK3777855T3 (da) Fremgangsmåder til behandling af fibrotiske sygdomme
DK3288577T3 (da) Adiponectin-peptidomimetika til behandling af øjenlidelser
DK3142664T3 (da) Sammensætninger og fremgangsmåder til behandling og diagnosticering af øjensygdomme
DK3132009T3 (da) Fremgangsmåde
DK3283210T3 (da) Fremgangsmåde
DK3164394T3 (da) Gls1-inhibitorer til behandling af sygdomme
PL3393468T3 (pl) Metody leczenia niedoboru odporności
DK3237621T3 (da) Varianter af human alpha-galactosidase
DK3307267T3 (da) Behandling af multipel sklerose
DK3848028T3 (da) Fremgangsmåder til behandling af øjenlidelser
DK3192524T3 (da) Hgf præparat egnet til behandling af neurologiske lidelser
DK3439661T3 (da) Fremgangsmåder til behandling af øjenlidelser
DK3151814T3 (da) Behandling af en hudlæsion
DK3143123T3 (da) Mikrorna-induktion af kardiologisk regenerering
DK3297619T3 (da) Terapeutiske anvendelser af L-4-chlorkynurenin